Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 421

1.

Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?

Brown JR, Wierda WG.

J Natl Compr Canc Netw. 2019 Nov;17(11.5):1408-1410. doi: 10.6004/jnccn.2019.5026.

PMID:
31766019
2.

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.

Tam CS, Siddiqi T, Allan JN, Kipps TJ, Flinn IW, Kuss BJ, Opat S, Barr PM, Tedeschi A, Jacobs R, Badoux XC, Ghia P, Sukbuntherng J, Salem AH, Russell K, Eckert K, Zhou C, Ninomoto J, James DF, Wierda WG.

Blood. 2019 Nov 13;134(Supplement_1):35. doi: 10.1182/blood-2019-121424.

PMID:
31724017
3.

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL).

Sharman JP, Banerji V, Fogliatto LM, Herishanu Y, Munir T, Walewska R, Follows G, Karlsson K, Ghia P, Corbett G, Walker P, Egyed M, Jurczak W, Salles G, Janssens A, Cymbalista F, Wierda WG, Coutre S, Pagel JM, Skarbnik A, Kamdar M, Woyach J, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC.

Blood. 2019 Nov 13;134(Supplement_1):31. doi: 10.1182/blood-2019-128404.

PMID:
31724010
4.

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL).

Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG.

Blood. 2019 Nov 13;134(Supplement_1):34. doi: 10.1182/blood-2019-131847.

PMID:
31724006
5.

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.

Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E.

Am J Hematol. 2019 Nov 3. doi: 10.1002/ajh.25671. [Epub ahead of print]

PMID:
31682008
6.

STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.

Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z.

J Immunol. 2019 Dec 1;203(11):3078-3085. doi: 10.4049/jimmunol.1900389. Epub 2019 Oct 23.

PMID:
31645416
7.

First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL).

Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T.

Leuk Lymphoma. 2019 Sep 30:1-5. doi: 10.1080/10428194.2019.1660967. [Epub ahead of print] No abstract available.

PMID:
31566032
8.

Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know.

Shah M, Rajha E, DiNardo C, Muckey E, Wierda WG, Yeung SJ.

Ann Emerg Med. 2019 Sep 24. pii: S0196-0644(19)30583-9. doi: 10.1016/j.annemergmed.2019.07.015. [Epub ahead of print] Review.

PMID:
31561995
9.

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S.

Blood. 2019 Nov 21;134(21):1811-1820. doi: 10.1182/blood.2019002118.

PMID:
31558467
10.

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ.

Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19.

PMID:
31543463
11.

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.

Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG.

Blood. 2019 Nov 28;134(22):1951-1959. doi: 10.1182/blood.2019001077.

PMID:
31537528
12.

Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.

Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS.

Cancer Immunol Res. 2019 Dec;7(12):2036-2051. doi: 10.1158/2326-6066.CIR-19-0152. Epub 2019 Sep 17.

PMID:
31530560
13.

Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.

Jain N, Gandhi V, Wierda W.

N Engl J Med. 2019 Aug 22;381(8):789. doi: 10.1056/NEJMc1908754. No abstract available.

PMID:
31433937
14.

The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.

Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG.

Br J Haematol. 2019 Oct;187(1):e1-e4. doi: 10.1111/bjh.16117. Epub 2019 Jul 25. No abstract available.

PMID:
31344256
15.

Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.

Yalniz FF, Wierda WG.

Drugs. 2019 Aug;79(12):1287-1304. doi: 10.1007/s40265-019-01163-4. Review.

PMID:
31313099
16.

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.

Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC.

Blood. 2019 Aug 22;134(8):688-698. doi: 10.1182/blood.2019000490. Epub 2019 Jul 10.

17.

Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.

Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG.

Br J Haematol. 2019 Nov;187(3):307-318. doi: 10.1111/bjh.16042. Epub 2019 Jun 26.

PMID:
31243771
18.

Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?

Wierda WG.

Clin Adv Hematol Oncol. 2019 Apr;17(4):214-216. No abstract available.

PMID:
31188811
19.

Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells.

Chen LS, Keating MJ, Wierda WG, Gandhi V.

Leuk Lymphoma. 2019 Dec;60(12):3063-3066. doi: 10.1080/10428194.2019.1622098. Epub 2019 Jun 4. No abstract available.

PMID:
31161836
20.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W.

N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

PMID:
31141631

Supplemental Content

Loading ...
Support Center